“Valeant Doesn’t Look Cheap” – Barron’s
Over the weekend, Barron’s magazine featured our research for the fourth time in 2016 and 20th time since 2014. This time, Barron’s featured our research on Valeant Pharmaceuticals (VRX).
Kyle Guske II, Senior Investment Analyst, MBA